NEWS 18 January 2023 ChatGPT listed as author on research papers: many scientists disapprove At least four articles credit the AI tool as a co-author, as publishers scramble to regulate its use. Chris Stokel-Walker Nature 613, 620-621 (2023) doi: https://doi.org/10.1038/d41586-023-00107-z The artificial-intelligence chatbot ChatGPT is disrupting many industries, including academia.Credit: Iryna Imago/Shutterstock The artificial-intelligence (AI) ...

Research Letter  January 17, 2023 Timing of Blood Draws Among Patients Hospitalized in a Large Academic Medical Center César Caraballo, Shiwani Mahajan, Karthik Murugiah, et al JAMA. 2023;329(3):255-257. doi:10.1001/jama.2022.21509 Sleep is a key element of patient care and experience, and its deprivation among hospitalized patients is an important stressor that increases their risk of adverse events during and after hospitalization.1-3&...

Original Investigation  Caring for the Critically Ill Patient January 17, 2023 Effect of Early High-Flow Nasal Oxygen vs Standard Oxygen Therapy on Length of Hospital Stay in Hospitalized Children With Acute Hypoxemic Respiratory Failure: The PARIS-2 Randomized Clinical Trial Donna Franklin, Franz E. Babl, Shane George, et al JAMA. 2023;329(3):224-234. doi:10.1001/jama.2022.21805 Key Points Question  Does the early use of nasa...

Original Investigation  January 17, 2023 Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial Robert J. Mentz, Kevin J. Anstrom, Eric L. Eisenstein, et al JAMA. 2023;329(3):214-223. doi:10.1001/jama.2022.23924 Key Points Question  Does torsemide reduce all-cause mortality compared with furosemide in patients with heart fail...

ORIGINAL ARTICLE Early Treatment with Pegylated Interferon Lambda for Covid-19 Gilmar Reis, Eduardo A.S. Moreira Silva, Daniela C. Medeiros Silva, et al N Engl J Med 2023; 388:518-528DOI: 10.1056/NEJMoa2209760 Abstract BACKGROUND The efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19) is unclear. METHODS We conducted a randomized, control...

ARTICLES| VOLUME 11, ISSUE 1, P87-96, JANUARY 01, 2023 Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study Joshua J Solomon, Sonye K Danoff, Felix A Woodhead, et al. Lancet Respir Med 2023; 11: 87-96 Published:September 05, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00260-0 Summary Background Inters...

Research Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study Barak Mizrahi, Tamar Sudry, Natalie Flaks-Manov, et al BMJ 2023; 380 doi: https://doi.org/10.1136/bmj-2022-072529 (Published 11 January 2023)Cite this as: BMJ 2023;380:e072529 Abstract Objectives To determine the clinical sequelae of long covid for a year after infection in patients with mild disease and to evaluate its association with age, sex, SARS-CoV-...

Antibiotic Review Kit for Hospitals Antibiotic overuse is a growing problem in healthcare. Antimicrobial resistance has a significant impact on global public health, and its effects are similar to that of malaria and HIV. Antimicrobial resistance caused nearly 4.95 million deaths in 2019. In addition, antimicrobial resistance has significant economic consequences on healthcare systems.  Human antibiotic consumption is the primary cause of antimicrobial resi...

ARTICLES| VOLUME 11, ISSUE 1, P45-54, JANUARY 01, 2023 Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial Toby M Maher, Veronica A Tudor, Peter Saunders, et al. Lancet Respir Med 2023; 11: 45-54 Open Access Published: November 11, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00359-...

ICU是救治重症患者的主战场，但我国重症医疗资源紧缺。应用机器人、深度学习、大数据等技术研发重症监护机器人有其临床价值，可以降低医护工作强度、减少感染风险、提升医疗质量。 基于以上，北京积水潭医院联合合肥工业大学、水木东方医用机器人技术创新公司等9家单位，联合开展“国家重点研发计划-巡诊查房智能化机器人研发”项目，目前机器人可能具备生理监测、病情评估、互动式查体、远程操控、情感陪护等功能。为进一步明确全国范围内各医院ICU的临床痛点及主要临床需求，指导医工研发，现拟邀请您完成以下...